Abstract

Provided herein are methods of culturing ex-vivo tissue, comprising culturing a tissue slice under a highly oxygenated atmosphere in the presence of an amount of an agent and agitating the culture. Also provided are methods of determining a therapeutically effective dose of an agent in the treatment of a disease or disorder using the ex-vivo tissue culture method.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/09 - Tumour cells
• A01N 1/02 - Preservation of living parts
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

Methods of inhibiting eIF4G1 binding to eIF1, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4G1-eIF1 binding and there use in treating disease are also provided.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/415 - 1,2-Diazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings

Abstract

Disclosed herein are broad-spectrum Coronavirus entry inhibitor compounds and methods of use thereof. Methods disclosed herein include inhibiting Coronavirus infection, treating a Coronavirus infection, and treating a subject at risk of contracting a Coronavirus infection. The compounds described herein target entry of Coronaviruses downstream of binding of the viral receptor.

IPC Classes  ?

• C07D 233/84 - Sulfur atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/275 - NitrilesIsonitriles
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

Disclosed herein are genetically modified plants having altered biological activity of 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Methods of producing these genetically modified plants are also disclosed.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Abstract

There is provided an isolated fungus belonging to the genus Kazachstania, a composition comprising same, and methods of using same, such as for preventing or treating an infection, a disease, or both.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61P 31/10 - Antimycotics
• C12R 1/645 - Fungi

Abstract

An assembly, system, and method for photodynamic therapy (PDT) of a target tissue utilizing a delivery apparatus and a displacement control arrangement. The delivery apparatus comprises a flexible needle device with an elongated flexible tube having a fiber-receiving lumen, extendable in a proximal-distal direction along a delivery axis, and with a pointed, needle-like distal tip for penetrating said tissue. An optical fiber is insertable and axially displaceable within said lumen and couplable at its proximal end to a light source, emitting a PDT-effective light at a wavelength applicable for said PDT. The fiber's distal end portion has a light-diffusing section for emitting light from within the fiber in one or more directions and has one or more X-ray markers. The displacement-control arrangement is couplable to a proximal portion of the flexible needle device and to a proximal portion of the optical fiber accommodated within the flexible needle device with the proximal portion projecting out of the proximal end of the flexible needle device, and comprises an axial displacement arrangement configured for controlled axial displacement of said delivery apparatus. The delivery apparatus may also comprise a delivery catheter extending in a proximal-to-distal direction and has a working channel that can accommodate the flexible needle device.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

A co-polymeric compound represented by Formula (I): wherein the variables are described in the specification and claims, a composition comprising a hydrogel or a composite material containing a hydrogel what has incorporated therein the co- polymeric compound and a process of preparing such a composition, a method of lowering a friction coefficient of a hydrogel or of a composite material containing a hydrogel effected by forming the hydrogel in the presence of the co-polymeric compound, a method of inhibiting biofilm formation on a surface of a substrate comprising contacting the substrate with the composition or composite material, and an article-of-manufacturing comprising the composition or composite material, are provided.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 29/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/08 - Materials for coatings
• A61L 29/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 29/14 - Materials characterised by their function or physical properties

Abstract

A system and methods for electron beam imaging or electron beam spectroscopy. The system comprising: a transmission electron microscope (TEM) having a back focal plane; one or more laser-based devices, configured to shift a predetermined portion of an electron wave to an energy that is different from the energy originally provided by the electron source of the TEM; and an electron energy filter that is configured to accept electron waves, at the energy provided by the electron source of the TEM, and further configured to reject electron waves shifted to a different energy by the laser device.

IPC Classes  ?

• H01J 37/22 - Optical or photographic arrangements associated with the tube
• H01J 37/26 - Electron or ion microscopesElectron- or ion-diffraction tubes

Abstract

Provided herein a biodegradable composite comprising a biodegradable polymer and bio-crystals, wherein the bio-crystals are in a concentration of between 1 wt % to 50 wt % of the biodegradable polymer.

IPC Classes  ?

• C08K 5/17 - AminesQuaternary ammonium compounds
• C08B 11/02 - Alkyl or cycloalkyl ethers
• C09D 7/63 - Additives non-macromolecular organic
• C09D 101/28 - Alkyl ethers

Abstract

Methods of predicting clinical outcome in a subject suffering from cancer, detecting non-liver cancer in a subject, and methods of treating or preventing cancer or cancer-associated cachexia are provided. Synthetic lipid nanoparticles encapsulating an mRNA encoding for HNF4A and composition comprising same are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• C12N 15/78 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
• A61P 35/00 - Antineoplastic agents
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

Provided herein a supramolecular assembly comprising a solid porous particle comprising a single-stranded polynucleotide encapsulated by non-covalent organic structure. Specifically, the non-covalent organic structure is melamine-cyanurate, and the single-stranded polynucleotide is ssDNA or ssRNA.

IPC Classes  ?

• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more of the molecule 1′-2′ glycosyl cyclic adenosine diphosphate ribose (1′-2′ gcADPR), 1′-3′ gcADPR or Tad1 protein.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

A composite, an article comprising the composite, and a method of making the composite are disclosed. The composite may include an elastic polymeric substrate and metal nanostructures attached to a surface of the elastic polymeric substrate; wherein: each of said metal nanostructures comprises a first portion embedded within the elastic polymeric substrate and a second portion exposed to an ambient; said metal nanostructures have lateral dimension between 1 to 1000 nm, said metal nanostructures have a thickness of between 5 to 200 nm.

IPC Classes  ?

• G10N 27/12 -

Abstract

A polymeric compound is disclosed herein, having the general formula I: A polymeric compound is disclosed herein, having the general formula I: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

IPC Classes  ?

• C08F 130/02 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C07F 9/10 - Phosphatides, e.g. lecithin

Abstract

Nucleic acid molecules comprising a heterologous promoter and an open reading frame encoding a T cell receptor (TCR) alpha chain comprising a CDR-A3 of SEQ ID NO: 3 and an open reading frame encoding a TCR beta chain comprising a CDR-B3 of SEQ ID NO: 4 are provided. Isolated populations of T cells and compositions comprising the nucleic acid molecules as well as methods of treating cancer are also provided.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

One or more pMPC conjugate(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided. Use of the pharmaceutical composition for delivering a cargo (e.g. a nucleotide) to a subject is also provided.

IPC Classes  ?

• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

Genetically modified phages are provided. Accordingly, there is provided a genetically modified phage comprising a polynucleotide encoding an anti-defense system polypeptide. Also provided are methods of producing and using same.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This invention is directed to a method of electrocatalytic reduction of dinitrogen (N2) to ammonia using a poly oxometalate catalyst, an alkali metal cation and a donor of a proton and/or an electron.

IPC Classes  ?

• C25B 1/27 - Ammonia
• C25B 11/085 - Organic compound

Abstract

Compositions and methods for treating or preventing an infection by an intracellular pathogen in a subject in need thereof are provided.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/42 - Oxazoles
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/12 - Antivirals

Abstract

The present invention relates to a quantum computing device based on manipulating Majorana Zero Mode excitations (MZMs) in topological superconducting regions formed in a tapered nanowire or similar structure. The tapering of the NW structure results in the formation of discrete regions of topological superconductivity having MZMs at their end boundaries, and thereby facilitates establishing the MZMs without delicate tuning procedures. A quantum swap gate is provided, utilizing two such structures in contact and disposed orthogonally to one another. Applying a magnetic field selectively lengthens the region of one structure while shortening the region of the other, allowing voltage and magnetic field changes to manipulate and interchange the MZM quantum states of the two structures to effect the swap operation.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Using a pre-trained and fixed Vision Transformer (ViT) model as an external semantic prior, a generator is trained given only a single structure/appearance image pair as input. Given two input images, a source structure image and a target appearance image, a new image is generated by the generator in which the structure of the source image is preserved, while the visual appearance of the target image is transferred in a semantically aware manner, so that objects in the structure image are “painted” with the visual appearance of semantically related objects in the appearance image. A self-supervised, pre-trained ViT model, such as a DINO-VIT model, is leveraged as an external semantic prior, allowing for training of the generator only on a single input image pair, without any additional information (e.g., segmentation/correspondences), and without adversarial training. The method may generate high quality results in high resolution (e.g., HD).

IPC Classes  ?

• G06F 3/14 - Digital output to display device
• G06T 7/11 - Region-based segmentation
• G06V 10/54 - Extraction of image or video features relating to texture
• G06V 10/56 - Extraction of image or video features relating to colour
• G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations

Abstract

A nanowire having a magnetic property is disclosed. The nanowire comprising: a ternary Zintl phase of a stoichiometric formula of X3Y2Z4, wherein the ternary Zintl phase is in a crystalline state; and wherein: X is selected from Eu, Ca, Sr, and Ba; ¥ is In or Al; and Z is As or P.

IPC Classes  ?

• C30B 1/10 - Single-crystal growth directly from the solid state by solid state reactions or multi-phase diffusion
• C30B 23/00 - Single-crystal growth by condensing evaporated or sublimed materials
• C30B 29/10 - Inorganic compounds or compositions
• C30B 29/40 - AIIIBV compounds
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape

Abstract

Provided herein a PINCH (Polymerization Inducing Chimera) compound targeting a homomeric protein of interest, wherein the PINCH compound comprises at least two protein binder groups that target the homomeric protein of interest and induces its polymerization.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
• C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Abstract

A system (20) for quantum computing includes an array of qubits (40) and a radiation source (28), which applies simultaneously to multiple qubits in the array radiation including a set of spectral components in multiple vibrational sidebands of an internal transition frequency of the qubits with different, respective complex amplitudes. The sidebands are generated by a group of the normal modes having a minimal spacing Δf between the respective vibrational frequencies. A controller (32) initializes a multi-qubit gate, including at least five of the qubits, to an initial state and drives the radiation source to apply the radiation to each of the qubits with respective complex amplitudes of the spectral components in the set selected so as to switch the multi-qubit gate to a target state within a gate time that is less than 50/Δf.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers

Abstract

Non-invasive methods of detecting pathology of the bone marrow comprising receiving a metacell model of a plurality of metacell types based on single cell RNA sequencing (scRNA-seq) of CD34 positive cells from peripheral blood and comparing it to control values of metacells of CD34 positive cells from peripheral blood of healthy subjects are provided. Non-invasive methods of predicting the percentage of blasts in the bone marrow and of calculating an IPSS-M risk score are also provided, as are systems for performing the methods of the invention.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]
• G06N 20/20 - Ensemble learning
• G16B 5/20 - Probabilistic models
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/20 - Supervised data analysis
• G16B 40/30 - Unsupervised data analysis

Abstract

This invention provides nanostructures comprising a base. and nano-protrusions attached to the base. The invention further provides arrays of such nanostructures on substrates. Also provided by this invention are analysis and catalysis. separation and purification systems and methods. comprising or making use of the novel nanostructures. Particles and films comprising nano-protrusions are included in this invention as well.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Methods of treating a subject with cancer with a recombinant polypeptide including an antigenic peptide covalently linked to a DRα1 domain or portion thereof comprising a glutamine residue at a position corresponding to amino acid 45 of SEQ ID NO: 1 or SEQ ID NO: 2 are provided. In some examples, the subject is resistant to immune checkpoint blockade treatment and/or has a tumor that does not express a BRAF mutation.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 19/00 - Hybrid peptides

Abstract

A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to medical assemblies and devices designed to capture and remove particulates and debris from a patient's body. In one example, a medical assembly can include a delivery shaft defining a working channel, and a debris removal device axially movable through the working channel. The debris removal device includes a main shaft and at least one debris capture segment attached to the main shaft. The debris capture segment includes a plurality of outwardly biased filaments, and is configured to transition between a compacted state when disposed inside the working channel or inside a lumen of a sleeve that can be optionally disposed around the main shaft, and an expanded state when exposed out of the working channel and/or lumen of the sleeve.

IPC Classes  ?

• A61B 17/221 - Calculus gripping devices in the form of loops or baskets

Abstract

The present invention provides polynucleotide sequences encoding a protein belonging to a decarboxylating (DC) enzyme family and/or a protein belonging to a hydroxylating (CYP) enzyme family. Further provided are a plasmid including the polynucleotide, a transgenic cell, and/or a plant including same. Further provided is a method for synthesizing mescaline.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

This invention is directed to a catalytic hydrogenation process for the preparation of 1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)-2-(tert-butylamino)ethanol, which is an intermediate for the preparation of Salbutamol. This invention is directed to a catalytic hydrogenation process for the preparation of 1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)-2-(tert-butylamino)ethanol, which is an intermediate for the preparation of Salbutamol.

IPC Classes  ?

• C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony

Abstract

S. aureusE. coli E. coli strains.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 31/04 - Antibacterial agents

Abstract

Liposomes, and pharmaceutical compositions comprising same, for use in treating biofilm in a subject in need thereof are disclosed herein. The liposomes comprise a bilayer-forming lipid; a polymer-lipid conjugate having the general formula I, as described and defined in the specification; a positively-charged lipidic agent, incorporated within a lipid bilayer and/or on a surface of the liposome; and a therapeutically active agent, bound to a surface of the liposome and/or within a lipid bilayer and/or core of the liposome.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61P 31/04 - Antibacterial agents

Abstract

Methods for decompressing a multiplexed-image, of C different channels, acquired to identify P targets in a tissue sample, where the targets are combinatorically labeled by at least C different labeling-elements, which are configured to be detected by the C different channels, and where P > C. The method comprising processor implemented step of: applying the multiplexed-image as an input to a trained NN. The NN is configured to output a tensor B, having P binary -images each having binary-pixels, each binary -image p per a different molecule p of the P molecules (where p = l,2,...,Py, wherein a pixel (ij; i = 1,2, = 7,2, in a binary-image p having a value of one (7) indicates that pixel (zj) is expected to contain a signal of its associated molecule p.

IPC Classes  ?

• G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

A multispecific antibody is provided. The antibody comprises a first antigen binding moiety, which specifically binds to an immune checkpoint protein on intratumor T cells and a second antigen binding moiety which specifically binds to a conventional dendritic cell 1 (cDC1). Also provided are uses of such antibodies in cancer treatment.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/46 - Hybrid immunoglobulins

Abstract

The present disclosure relates to catheter assemblies (100) designed to provide fluid communication between an organ in a patient's body and the external environment. Such a catheter assembly (100) includes an indwelling catheter (102) equipped with an anchoring mechanism (110) at a distal portion (104) thereof and an external tube (150) configured to frictionally engage with a proximal end portion (128) of the indwelling catheter. The frictional force between corresponding engagement surfaces of the indwelling catheter (102) and the external tube (150) is configured to allow disengagement therebetween in response to a pull force equal to or greater than a threshold separating pull force not greater than 20N for a duration of no more than 10 seconds, wherein the threshold separating pull force is designed to be lower than the pull force required to cause dislodgment of the indwelling (102) catheter from the patient's body.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61M 27/00 - Drainage appliances for wounds, or the like
• A61M 39/10 - Tube connectors or tube couplings

Abstract

Provided herein noncovalent hybrids comprising carbon nanotubes (CNTs) and aromatic compounds, composites based on them, process of preparation and uses thereof; wherein the hybrids possess superior mechanical and electrical properties.

IPC Classes  ?

• C01B 32/174 - DerivatisationSolubilisationDispersion in solvents
• B01D 17/02 - Separation of non-miscible liquids
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C01B 32/159 - Carbon nanotubes single-walled
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 101/32 - Hydrocarbons, e.g. oil
• C08K 9/04 - Ingredients treated with organic substances
• C09D 5/03 - Powdery paints
• C09D 5/24 - Electrically-conducting paints
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/36 - Nanostructures, e.g. nanofibres, nanotubes or fullerenes
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H05K 9/00 - Screening of apparatus or components against electric or magnetic fields

Abstract

The disclosure presented herein provides DNA constructs, recombinant cells comprising thereof, system comprising thereof, bacterial probes, and/or a recombinant cell decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying cells, preferably bacteria cells, and methods for using thereof.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

Provided herein is an apparatus for electrolytic atomic hydrogen decrepitation and methods of use thereof.

IPC Classes  ?

• C25C 5/00 - Electrolytic production, recovery or refining of metal powders or porous metal masses
• B22F 9/02 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes

Abstract

The present invention is directed to a pharmaceutical composition including a therapeutically effective amount of an agent capable of inhibiting an active site of a matrix metalloprotease (MMP-7) protein, and use of same in a method for treating endometriosis or ameliorating at least one symptom associated therewith, in a subject in need thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

A method of analyzing nucleosomes is provided. The method comprising: (a) isolating a plurality of nucleosome molecules from a biological sample; (b) enzymatically linking adenine nucleotides to free DNA ends of the plurality of nucleosome molecules, wherein at least a portion of the adenine nucleotides comprises a label, such that the plurality of nucleosome molecules become attached to a labeled poly(A) tail; (c) hybridizing the plurality of nucleosome molecules attached to the labeled poly(A) tail to a solid support coated with poly(T); and (d) imaging the solid support, whereby the plurality of nucleosome molecules are visualized.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6804 - Nucleic acid analysis using immunogens

Abstract

Systems and methods for a quantum computing include a plurality of photonic processing stages, a plurality of heralding-free connections, and circuitry configured to regulate photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage. Each heralding-free connection is located between adjacent photonic processing stages. Each photonic processing stage includes at least two of an optical switch, a beam splitter, a waveguide or a photon generator. Methods include transmitting or receiving a plurality of photons via a plurality of heralding-free connections, and regulating photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• H01L 29/66 - Types of semiconductor device
• H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier

Abstract

A system and method of determining efficacy of treatment by at least one processor may include receiving, from at least one camera, images depicting motion of an animal that may be treated with a predetermined substance of interest. Said processor may extract from the images, a plurality of motion features representing motion of at least one specific body part of the animal, and apply a dimensionality reduction algorithm on the plurality of motion features, to obtain a latent vector representing the plurality of motion features in a latent space. The latent vector may include a plurality of latent features. Said processor may subsequently calculate a value of a behavioral indicator, representing a behavior of the animal, based on the latent features of the latent vector, and determine efficacy of the treatment based on the behavioral indicator value.

IPC Classes  ?

• G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition

Abstract

A quantum computing system, method, and computer readable medium involves initializing a state of a resonator-coupled quantum emitter having at least four levels arranged in an N-configuration, the N-configuration having a first ground state, a second ground state, a first excited state and a second excited state. A frequency of a first transition between the first ground state and the first excited state is tuned, a frequency of a second transition between the second ground state and the second excited state is tuned, and a frequency of a third transition between the second ground state and the first excited state is tuned. A plurality of photons are fed at a frequency corresponding to the frequency of the second transition, thereby entangling the plurality of photons to the resonator-coupled quantum emitter. Likewise, a photon at a frequency corresponding to the frequency of at least one of the first transition or the third transition is fed, thereby mapping a state of the resonator-coupled quantum emitter into a photon.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G21K 5/00 - Irradiation devices

Abstract

The present disclosure relates to drainage devices designed to enable drainage of bodily fluids while reducing the risk of drainage openings being clogged by tissues surrounding the device. In one example, a drainage device comprises a drainage tube and a porous plug attached to a distal portion of the drainage tube. The porous plug defines a plurality of pores that includes interconnected channels fluidly connecting between pore outer openings along an exposed outer surface of the plug, and pore inner openings along an inner uncovered surface of the plug, such that upon application of suction to the drainage tube, bodily fluid can flow, through the pore outer openings, pore interconnected channels, and pore inner openings, towards a lumen of the drainage tube.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

Systems and methods for generating photonic graph states for quantum computing include coupling a quantum emitter to a cavity, generating a first dirty photon having a first temporal profile, using the first dirty photon to form a first photonic qubit, generating a second dirty photon having a second temporal profile, using the second dirty photon to form a second photonic qubit, using the quantum emitter coupled to the cavity to entangle the first photonic qubit with the second photonic qubit to form a pair of entangled photonic qubits, and using the pair of entangled photonic qubits for quantum computation.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A quantum computing system, method and computer readable medium involve a vacuum chamber, an atom source input associated with the vacuum chamber, a Photonic Integrated Circuit (PIC) having an interaction region configured to interact with an atom from the atom source, a coupling location for atom positioning, a trapping laser for trapping the atom in the coupling location, an excitation laser for manipulating an electronic state or a nuclear state of the atom, a waveguide for guiding input light to the coupling location, and an output channel for directing quantum light generated at the coupling location, out of the vacuum chamber as a resource for quantum computing. The coupling location is associated with the PIC, and the interaction region of the PIC is arranged for at least partial exposure to the vacuum.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A system for predicting probability for developing a liver associated disease, comprises a data processor which obtains parameters extracted from a body liquid test applied to a healthy subject, and feeds a machine learning procedure with the parameters. The machine learning procedure is trained for predicting probabilities for liver associated disease, and the processor receives from procedure an output indicative of a probability that the subject is expected to develop a liver associated disease.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Provided herein a composite comprising a multi-layered structure comprising at least one layer of multi-walled carbon nanotube (MWCNT) and at least one layer of single-walled carbon nanotube (SWCNT); and its use as a cathode for e.g. LSBs (lithium sulfur batteries).

IPC Classes  ?

• C01B 32/174 - DerivatisationSolubilisationDispersion in solvents
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/052 - Li-accumulators

Abstract

Multipotent lung progenitor cells for lung regeneration are provided. Accordingly, there are provided methods of expanding in culture an isolated population of pulmonary cells, methods of qualifying suitability of an isolated population of pulmonary cells for administration to a subject in need thereof, and methods of generating an isolated population of pulmonary cells comprising selecting a cell population being double positive for expression of epithelial and endothelial cell markers. Also provided are isolated populations of pulmonary cells, pharmaceutical compositions comprising same and uses of same.

IPC Classes  ?

• A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

Provided herein are genetically modified cells and genetically modified plants having increased or decreased expression of a cellulose synthase like G (CSLG) enzyme. These cells and plants may have an increased or decreased content a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin, compared to a corresponding unmodified cell or plant. Also provided herein are methods of producing a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a genetically modified cell, as well as methods of reducing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part, and methods of increasing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part.

IPC Classes  ?

• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• C12N 9/10 - Transferases (2.)
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A method for quantum computing includes defining a quantum computation including a sequence of computing steps in which multiple quantum operations are performed in parallel in each step. An array of ions (40) in an ion trap (24) is segmented into first computational segments (110) including groups of adjacent ions separated by first barrier ions (112) between the groups, by optically confining the barrier ions. Excitation fields are applied to the ions in the computational segments so as to cause the groups of ions to carry out the quantum operations in a first step in the sequence. After completing the first step, the array is reconfigured into second computational segments by optically confining second barrier ions, at least some of which are different from the first barrier ions, while retaining at least some coherence from the first computational segments to the second computational segments.

IPC Classes  ?

• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

This invention provides doped ceria-based materials exhibiting electrostriction properties and methods of preparation thereof.

IPC Classes  ?

• C01F 17/235 - Cerium oxides or hydroxides
• C01G 25/00 - Compounds of zirconium

Abstract

Recombinant peroxidase enzymes are disclosed having mutations that increase yield when expressed in yeast cells as compared to their corresponding wild-type peroxidase enzyme. Methods of generating are also disclosed as well as uses thereof.

IPC Classes  ?

• C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material

Abstract

A transport line for a very high energy electron (VHEE) beam with a wide energy spread produced by a laser plasma accelerator (LPA) includes three quadrupoles and a collimator. The three quadrupoles focus the VHEE beam vertically and horizontally to provide a very high energy dose at a pre-defined depth within a body. The collimator is located after the three quadrupoles and filters out low energy particles.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Provided herein a polyoxometalate compound represented by formula (I): (Q)n[XMaMbMc(La)(Lb)(Lc)W9O37] (I) or a solvate thereof; and a method of electrocatalytic reduction of carbon dioxide (CO2) using the polyoxometalate compound.

IPC Classes  ?

• C25B 11/085 - Organic compound
• C01B 33/20 - Silicates
• C07F 19/00 - Metal compounds according to more than one of main groups
• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/26 - Reduction of carbon dioxide
• C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide

Abstract

This invention is directed to modified proteins or modified peptides (modified by an electrophile, such as acrylamide or acrylate) for covalent binding with target proteins.

IPC Classes  ?

• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides

Abstract

An electrochemical decontamination method of removing fluorinated organic compound(s) (FOC(s)) from an aqueous stream, comprising applying electric voltage across electrodes in contact with the FOC(s)-containing aqueous stream in the presence of at least one Mn+and at least one Ak-, wherein Mn+is a reducible cation of a transition metal selected from the group consisting of iron, nickel, manganese and copper that can assume multiple oxidation states and Ak- is an oxidizable anion, which is chloride or bromide.

IPC Classes  ?

• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 1/42 - Treatment of water, waste water, or sewage by ion-exchange
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
• C02F 101/36 - Organic compounds containing halogen
• C02F 103/34 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups
• C02F 103/36 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups from the manufacture of organic compounds
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis

Abstract

Provided herein are planar waveguides comprising a plurality of unit cells (81) or an array of unit cells which have a particular refractive index profile. This grid of unit cells, together with a reflecting structure (93) enables light to be reflected and redirected along a path within the waveguide. An optical bus is provided for multi-core processing. Methods of fabricating an array of unit cells for a planar waveguide involving depositing photoresist and thermal oxidation are also provided.

IPC Classes  ?

• G02B 6/43 - Arrangements comprising a plurality of opto-electronic elements and associated optical interconnections
• G02B 6/136 - Integrated optical circuits characterised by the manufacturing method by etching

Abstract

The presently disclosed subject matter relates to methods of using the spin-strain coupling in nanoparticles comprising defects or color centers, to provide a unique fingerprint. In particular, the methods are directed to spin parameters extracted from nitrogen vacancies in nanodiamonds.

IPC Classes  ?

• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
• G01R 33/32 - Excitation or detection systems, e.g. using radiofrequency signals
• G07D 7/00 - Testing specially adapted to determine the identity or genuineness of valuable papers or for segregating those which are unacceptable, e.g. banknotes that are alien to a currency
• G01N 21/64 - FluorescencePhosphorescence

Abstract

Apparatus for quantum computing, consisting of a superconducting shell (50) having a first surface of rotation (66) about a central axis (54), and a second surface of rotation (86), different from the first surface of rotation, about the central axis. The first surface terminates in a first rim (78), and the second surface has an aperture (90) and terminates in a second rim (102) congruent to the first rim. The first rim and the second rim are sealed together to enclose a microwave cavity (14A) within the shell. The apparatus further includes a superconducting qubit (12) formed on a substrate (16) which is mounted so that a portion of the substrate penetrates through the aperture, thereby coupling the superconducting qubit to the microwave cavity.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

−3 millibar, optical resonators tuned to a resonance of an alkali atom, and a trapping laser for maintaining the alkali atom within a mode of the optical resonators. An atom excitation laser induces photon emissions, a plurality of waveguides couple photons to and from the optical resonators, and a plurality of detectors detect a presence or absence of an atom-resonator coupling. A processor receives output signals from the detectors and controls optical switches for switching between two or more of the plurality of waveguides.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G02F 1/313 - Digital deflection devices in an optical waveguide structure
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• H01S 3/042 - Arrangements for thermal management for solid state lasers

Abstract

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

IPC Classes  ?

• C12P 13/22 - TryptophanTyrosinePhenylalanine3,4-Dihydroxyphenylalanine
• A23L 3/3463 - Organic compounds; Microorganisms; Enzymes
• A23L 3/3526 - Organic compounds containing nitrogen
• A23L 3/3544 - Organic compounds containing hetero rings
• A23L 5/46 - Addition of dyes or pigments, e.g. in combination with optical brighteners using dyes or pigments of microbial or algal origin
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 13/04 - Alpha- or beta-amino acids
• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring
• C12P 19/02 - Monosaccharides

Abstract

A quantum computing method includes initializing a state of a resonator-coupled quantum emitter, receiving at least two photonic graph states, selecting at least one photon from each graph state, feeding the selected photons through an entangling gate via the resonator-coupled quantum emitter, and disentangling the resonator-coupled quantum emitter from the selected photons. Each of the at least two photonic graph states contains at least two photons. The disentangling includes at least one of detecting the state of the resonator-coupled quantum emitter or mapping the state of the resonator-coupled quantum emitter to a state of an additional photon.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An ultrasound scanning system includes an ultrasound scanner, a trained spare recovery neural network and a super resolution image generator. The ultrasound scanner views a patient after intravenous injection of microbubbles and then generates a sequence of ultrasound images. The sequence of ultrasound images is formed of a sequence of B-mode ultrasound images and a sequence of contrast enhanced ultrasound images corresponding to the B-mode ultrasound images. The trained sparse recovery neural network is trained on synthesized images of point sources and generates, for at least one image of the sequence of contrast-enhanced ultrasound images, a super-resolved image of locations of the microbubbles in that image. The super resolution image generator receives an output of the trained sparse recovery neural network and generates therefrom a super-resolved image of a microvasculature through which the microbubbles flowed.

IPC Classes  ?

• G06T 3/4053 - Scaling of whole images or parts thereof, e.g. expanding or contracting based on super-resolution, i.e. the output image resolution being higher than the sensor resolution
• A61B 8/08 - Clinical applications
• A61B 8/13 - Tomography
• G06T 3/4046 - Scaling of whole images or parts thereof, e.g. expanding or contracting using neural networks

Abstract

Provided are antibodies to TREM2 and Gpnmb. Also provided are compositions comprising the antibodies and methods of using same.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

Ex-vivo culture systems are provided. Accordingly there is provided a culture system comprising a culture medium and a precision-cut tissue slice placed on a tissue culture insert, wherein the precision-cut tissue slice is maintained in a highly oxygenated atmosphere containing at least 50% oxygen and wherein said culture is rotationally agitated facilitating intermittent submersion of the tissue slice in the culture medium. Also provided are methods of culturing a tissue and methods of using the culture system for selecting a drug for the treatment of a disease.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed herein are 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.

IPC Classes  ?

• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

This invention provides a process for the preparation of aluminum scandium nitride films. This invention further provides Caluminum scandium nitride films and layers, and devices and systems comprising aluminum scandium nitride films.

IPC Classes  ?

• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/02 - Pretreatment of the material to be coated
• H10N 30/06 - Forming electrodes or interconnections, e.g. leads or terminals
• H10N 30/076 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing by vapour phase deposition
• H10N 30/079 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing using intermediate layers, e.g. for growth control
• H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators

Abstract

Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 333/48 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms

Abstract

Provided herein noncovalent hybrids comprising carbon nanotubes (CNTs) and aromatic compounds, composites based on them, process of preparation and uses thereof, e.g. as electrodes and in lithium-ion cells; wherein the hybrids possess superior mechanical and electrical properties.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/04 - Processes of manufacture in general
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/66 - Selection of materials
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

A system and method is presented for imaging a biological tissue, marked by metal particles, in at least one region of interest in the biological tissue. The system comprises: a frequency modulated continuous wave (FMCW) transceiver system comprising at least one radiation transmitter and at least one radiation receiver, the FMCW transceiver being configured to transmit series of millimeter wavelength signals to interact with each of said at least one region of interest and receive radiation originated within a field of view of the transceiver, and generate raw measured data indicative of received radiation; and a control system configured and operable to receive and process said raw measured data, the processing comprising extracting from said raw measured data, data indicative of radiation response of said metal particles to said interaction with the millimeter wavelength signals for each of said at least one region of interest, and determining map data indicative of a distribution of said metal particles within each region of interest.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01R 29/08 - Measuring electromagnetic field characteristics
• H01Q 1/00 - Details of, or arrangements associated with, antennas

Abstract

A monitoring system (100) is presented for monitoring vital signs of subject(s). The monitoring system (100) includes a control system (12) configured for signal communication with a frequency modulated continuous wave FMCW radar system (10) to process measured data which is received from a single-channel limited to either the in-phase or the quadrature component of receiver of said FMCW radar and which is in the form of a data matrix (DM) indicative of consecutive beat signals. The control system comprises a data processing utility comprising: a localization module (30) configured and operable to process the measured data indicative of said data matrix (DM) and provide support recovery data indicative of the received signals originated at localized one or more subjects; and a vital signs extraction module (32) configured and operable to analyze the support recovery data and monitor vital signs, such as respiration rate RR and heart rate HR, of said localized one or more subjects.

IPC Classes  ?

• A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves using microwaves or terahertz waves
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• G01S 13/88 - Radar or analogous systems, specially adapted for specific applications

Abstract

The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the prenyltransferase (PT) family. Further provided are an artificial nucleic acid molecule including the polynucleotide, a transgenic cell, tissue, or plant including same.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12P 7/42 - Hydroxy carboxylic acids

Abstract

A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a technique for flow crystallization. The system comprises a container having a bottom surface defining a first plane, the container including at least two planar magnetic surfaces being arranged in a spaced-apart manner along a first plane and being substantially parallel to a second plane; a magnetization vector of each of the magnetic surfaces being perpendicularly to the surface, wherein the container is configured such that the first plane is substantially perpendicularly to the second plane; wherein a cavity formed in between the planar magnetic surfaces is configured to accommodate a racemic mixture including different enantiomers such that each magnetic surface interacts differently with each of the different enantiomers to thereby enable enantio-selective crystallization. Therefore, the system of the present invention is based on enantio-separation of the crystals using magnetic surfaces.

IPC Classes  ?

• B01D 9/00 - Crystallisation
• B01D 9/02 - Crystallisation from solutions

Abstract

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/36 - ArsenicCompounds thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Intraluminal photodynamic therapy (PDT) of a target tumor tissue that is carried out from within a blood vessel is disclosed. The PDT method may be a vascular-targeted photodynamic therapy (VTP) or any other form of PDT where photosensitizer concentration in the blood vessel endothelium is not phototoxic. The PDT of this disclosure is carried out from within a blood vessel in the vicinity of the target tissue or organ with a light-diffusing section of an irradiating optical fiber being positioned within the confines of an inflatable balloon section of a balloon catheter, which is inflated during irradiation to occlude blood flow.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

The present invention provides a stirring-free scalable electrochemical reactor enabled by alternating current and uses thereof in a method of performing electrosynthesis of organic reaction.

IPC Classes  ?

• C25B 11/031 - Porous electrodes
• C25B 3/05 - Heterocyclic compounds
• C25B 3/07 - Oxygen containing compounds
• C25B 3/09 - Nitrogen containing compounds
• C25B 3/11 - Halogen containing compounds
• C25B 3/23 - Oxidation
• C25B 3/25 - Reduction
• C25B 9/15 - Flow-through cells
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 11/043 - Carbon, e.g. diamond or graphene
• C25B 13/05 - DiaphragmsSpacing elements characterised by the material based on inorganic materials

Abstract

Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/728 - Hyaluronic acid
• A61K 31/77 - Polymers containing oxygen of oxiranes
• A61K 31/79 - Polymers of vinyl pyrrolidone
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• B65D 35/00 - Pliable tubular containers adapted to be permanently deformed to expel contents, e.g. collapsible tubes for toothpaste or other plastic or semi-liquid materialHolders therefor
• B65D 75/36 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages

Abstract

In the absence of vaccines, chemotherapy is the main tool for treating parasitic diseases. As emergent resistant strains limit the utility of the few viable clinical options, new therapy is urgently needed to fight parasitic diseases. The present application relates to anisomycin analogs of Formula (I) or prodrug, solvates or pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions comprising same. These anisomycin analogs, prodrugs, solvates, or pharmaceutically acceptable salts thereof may be used for the treatment of parasitic infections and diseases, including protozoan diseases such as trypanosomiasis, leishmaniasis or toxoplasmosis.

IPC Classes  ?

• C07D 207/12 - Oxygen or sulfur atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 33/00 - Antiparasitic agents
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Methods for assessment and monitoring of mood in subjects with bipolar disorder are provided, based on changes in the level of cortisol in hair samples of patients. In particular, methods for assessment of depression and anxiety in subjects with bipolar disorder are provided, based on changes in cortisol levels in their hair over time. The methods of the present invention are particularly useful in monitoring, managing and adjusting treatment of subjects with bipolar disorder.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Conditioning protocols for use with anti-viral central memory CD8+ veto cells in haploidentical stem cell transplantation are provided. Accordingly, there is provided a method of treating a disease in a subject in need thereof, wherein the disease comprises pathological cells residing in a bone marrow of the subject, the method comprising: conditioning the subject under a pre-transplant conditioning protocol comprising total marrow irradiation; transplanting into the subject T cell depleted immature hematopoietic cells; administering to the subject cyclophosphamide; and administering to the subject veto non-graft versus host disease inducing cells.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the acyl activating enzyme (AAE) family. Further provided are an artificial nucleic acid molecule including the polynucleotide, a transgenic cell, tissue, or plant including same. Further provided are method for synthesizing an acyl coenzyme A (CoA).

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Abstract

A method of isolating an antibody is disclosed. The method comprises contacting a hydrophobic chelator, a non-ionic detergent and metal ions so as to generate an aggregate comprising the hydrophobic chelator, the detergent and the metal ions; and contacting the aggregate with a medium comprising the antibody under conditions that allow partitioning of the antibody into the aggregate. Kits for isolating the antibody are also disclosed.

IPC Classes  ?

• C07K 1/32 - ExtractionSeparationPurification by precipitation as complexes
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis

Abstract

The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

This invention is directed to substituted a methacrylamide compounds as targeted covalent protein binders and uses thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C09K 11/07 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials having chemically-interreactive components, e.g. reactive chemiluminescent compositions

Abstract

Combined treatment for cancer is provided. Accordingly, there is provided a method of selecting or determining therapeutic efficacy of a combination of agents for the treatment of cancer in a subject in need thereof, the method comprising: (i) culturing a cancerous tissue of the subject in an ex-vivo organ culture (EVOC) in the presence of a combination of an anti-cancer agent and an additional agent, said additional agent is inhibiting expression and/or activity of a target conferring innate resistance to said anti-cancer agent or increasing expression and/or activity of a target conferring innate sensitivity to said anti-cancer agent; and (ii) determining an anti-cancer effect of the combination on the tissue, wherein responsiveness of the tissue to the combination indicates the combination is efficacious for the treatment of the cancer in the subject. Also provided are methods of treating cancer with a combination of agent wherein cancerous tissue obtained from the subject demonstrates responsiveness to the combination of agents in an ex-vivo organ culture (EVOC).

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A quantum computing system includes a first resonator couplable to a first alkali atom, a second resonator couplable to a second alkali atom, and lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A method of increasing an amount of Chromodomain Helicase DNA Binding Protein 2 (CHD2) in a neuronal cell is provided. The method comprising introducing into the cell a nucleic acid agent that down-regulates activity or expression of human Chaserr, wherein the nucleic acid agent is directed at the last exon of human Chaserr, thereby increasing the amount of CHD2 in the neuronal cell.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/00 - Drugs for disorders of the nervous system
• G16B 30/10 - Sequence alignmentHomology search

Abstract

A recombinant bacteria which is genetically modified to express formate dehydrogenase (FDH), phosphoribulokinase (prk) and Ribulose-Bisphosphate Carboxylase/oxygenase (RuBisCo) is disclosed. The bacteria may be modified to be autotrophic.

IPC Classes  ?

• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/88 - Lyases (4.)